HomelandDefenseStocks. com Reports: More Billions for Biodefense – Are Vaccines the Answer?
HomelandDefenseStocks. com, (HDS) an investment news portal for the Homeland Defense and Security Sector, reports on treatments and vaccines in an exclusive featured article ”More Billions for Biodefense – Are vaccines the answer?“ following the recent signing of Project BioShield into law by the President. Project BioShield, a $5.6 Billion bill that will stockpile new vaccines and develop countermeasures to bioterrorism attacks, will fuel demand for biological and chemical weapons detection and protection solutions. Within the biodefense community the question is being raised whether we should spend more on post-exposure treatments?
POINT ROBERTS, WA (PRWEB) July 31, 2004
www. HomelandDefenseStocks. com, (HDS) an investment news portal for the Homeland Defense and Security Sector, reports on treatments and vaccines in an exclusive featured article ”More Billions for Biodefense – Are vaccines the answer?“ following the recent signing of Project BioShield into law by the President. Project BioShield, a $5.6 Billion bill that will stockpile new vaccines and develop countermeasures to bioterrorism attacks, will fuel demand for biological and chemical weapons detection and protection solutions. Within the biodefense community the question is being raised whether we should spend more on post-exposure treatments?
HDS does not make recommendations, but offers a unique, free information portal to investors to research news, articles, interviews and a growing list of participating public companies and featured profiled companies within the sector including: Aethlon Medical, Inc. (OTCBB: AEMD) and Markland Technologies, Inc. (OTCBB: MRKL).
More Billions for Biodefense – Are vaccines the answer?
By Allen Gibson, HomelandDefenseStocks. com
With the recent signing by the President of the Project Bioshield Act of 2004, the federal government has authorized $5.6 Billion dollars in spending over the next ten years to increase AmericanÂ’s security from biological attack.
Already, the government has purchased smallpox and anthrax vaccines – 75 million doses in the case of anthrax - as a key part of the Bioshield initiative. But is this a case of ‘fighting the last war’ or defending against the last terror attack?
A report out of the University of Pittsburgh suggests that the life sciences are at the beginning of a revolutionary period. Scientific understanding of living systems and how to manipulate them is expanding exponentially. The report, from The Center for Biosecurity at the U of P, suggests our strategy should be “an ambitious and aggressive scientific research, development, and production (R&D&P) program that delivers the diagnostic technologies, medicines, and vaccines needed to counter the range of bioweapons agents.”
Â…The doctors in charge of education for the National Center for Biodefense argue that less money should be spent on vaccine purchase and development, and more on post-exposure treatments.
Vaccines, say Drs. Ken Alibek and Charles Bailey, arenÂ’t going to be effective for civilian populations, since no one can know which specific agent to guard against, and the drugs must be administered in advance to be effective. Also, they say in a letter to the editor of the Biosecurity and Bioterror newsletter, it is far easier and takes fewer years to develop a weapons-grade disease than to produce a vaccine against it.
The immediate relevancy of programs other than vaccines was vividly demonstrated this July, when the FBI announced that Ricin compound was introduced into some baby food jars on the west coast. Minute amounts of Ricin can be fatal. The gaseous form of Ricin was used in the deadly Tokyo subway attacks a few years ago. And no vaccine or cure presently exists. Which means that new, non-vaccine; treatments are needed now, and will be needed in the future.
One example of how biotech can be repurposed to address the bioterror threat comes from Aethlon Medical (OTCBB: AEMD), who created a ‘Hemopurifier’ machine to strip viruses and toxins out of the blood of infected patients. Originally designed to treat HIV and Hep C, the company is now working with the National Center for Biodefense at George Mason University to develop filtration devices that could be used by both the military and civilian populations against Class A bioterror agents. The Company will use new FDA rules to test the devices on animal species and extrapolate safety data for humans, since human tests are obviously not practicable.
Full article: www. HomelandDefenseStocks. com/Companies/HomelandDefense/Articles/Biodefense. asp (http://www. HomelandDefenseStocks. com/Companies/HomelandDefense/Articles/Biodefense. asp )
HDS Featured Companies: Biological and chemical weapons detection and medical countermeasures: HDS is compensated by featured companies as disclosed below.
Aethlon Medical, Inc. (OTCBB: AEMD) www. AethlonMedical. com is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. The Company is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism.
Markland Technologies, Inc. (OTCBB: MRKL) www. marklandtech. com. is positioned in the chemical detection sector with its Shipboard Automatic Chemical Agent Detection and Alarm System (ACADA). The ACADA is an automatic chemical agent alarm system capable of detecting, warning and identifying blister and nerve agents simultaneously. The ACADA is man-portable, operates independently after system start-up, provides an audible and visual alarm, and provides communication interface to support battlefield automation systems.
HomelandDefenseStock. com list of public companies in the sector: www. InvestorIdeas. com/Companies/HomelandDefense/Articles/StockList. asp (http://www. InvestorIdeas. com/Companies/HomelandDefense/Articles/StockList. asp )
Disclaimer: ECON Corporate Services is the owner of the domain www. HomelandDefenseStocks. com.
The site does not make recommendations but offers an information portal to investors to research news, articles, and recent research. The site is currently compensated for by its "featured companies.” Markland Technologies, Inc. currently pays ECON $10,000 per month. Markland has issued shares to ECON in the past and these payments are for the purpose of including Markland in articles and other promotions. Aethlon Medical, mentioned in this article, pays $3000 per month plus restricted shares equivalent to $5000 per month.
Disclaimer: www. InvestorIdeas. com/About/Disclaimer. asp (http://www. InvestorIdeas. com/About/Disclaimer. asp )
HomelandDefenseStocks. com is a Registered WA Trade Name.
For more information contact:
Dawn Van Zant / Trevor Ruehs
Toll free: 800-665-0411
Email: dvanzant@homelanddefensestocks. com or truehs@homelanddefensestocks. com
# # #
